PT  - JOURNAL ARTICLE
AU  - Mengel, David
AU  - Soter, Ester
AU  - Ott, Julia Maren
AU  - Wacker, Madeleine
AU  - Leyva, Alejandra
AU  - Peters, Oliver
AU  - Hellmann-Regen, Julian
AU  - Schneider, Luisa-Sophie
AU  - Wang, Xiao
AU  - Priller, Josef
AU  - Spruth, Eike
AU  - Altenstein, Slawek
AU  - Schneider, Anja
AU  - Fliessbach, Klaus
AU  - Wiltfang, Jens
AU  - Hansen, Niels
AU  - Rostamzadeh, Ayda
AU  - Düzel, Emra
AU  - Glanz, Wenzel
AU  - Incesoy, Enise I.
AU  - Buerger, Katharina
AU  - Janowitz, Daniel
AU  - Ewers, Michael
AU  - Perneczky, Robert
AU  - Rauchmann, Boris
AU  - Teipel, Stefan
AU  - Kilimann, Ingo
AU  - Laske, Christoph
AU  - Sodenkamp, Sebastian
AU  - Spottke, Annika
AU  - Brustkern, Johanna
AU  - Brosseron, Frederic
AU  - Wagner, Michael
AU  - Stark, Melina
AU  - Kleineidam, Luca
AU  - Shao, Kai
AU  - Lüsebrink, Falk
AU  - Yakupov, Renat
AU  - Schmid, Matthias
AU  - Hetzer, Stefan
AU  - Dechent, Peter
AU  - Scheffler, Klaus
AU  - Berron, David
AU  - Jessen, Frank
AU  - Synofzik, Matthis
AU - the DELCODE study group
TI  - Blood biomarkers confirm subjective cognitive decline (SCD) as a distinct molecular and clinical stage within the NIA-AA framework of Alzheimer’s disease
AID  - 10.1101/2024.07.10.24310205
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.07.10.24310205
4099  - http://medrxiv.org/content/early/2024/07/10/2024.07.10.24310205.short
4100  - http://medrxiv.org/content/early/2024/07/10/2024.07.10.24310205.full
AB  - Introduction Subjective cognitive decline (SCD) is proposed to indicate transitional stage-2 in the AD continuum, yet longitudinal fluid biomarker data for this stage is scarce. We investigated if blood-based biomarkers in amyloid-positive individuals with SCD (A+SCD) support stage-2 as distinct from AD stages-1 and -3 and identify those at high risk for progression.Methods We analyzed plasma phospho-tau-181 (p181) and neurofilament-light-chain (NfL) in a prospective multicenter study of 460 participants across the AD continuum, assessing their association with cognition, hippocampal atrophy, and clinical progression.Results Baseline plasma p181 was elevated and increased faster in A+SCD compared to amyloid-positive cognitively unimpaired (A+CU) individuals (stage-1). NfL rose across A+CU, A+SCD, and A+MCI (stage-3). In A+SCD, higher p181 predicted cognitive decline and transition to MCI.Discussion Plasma p181 provides biomarker evidence for A+SCD as a distinct pre-dementia AD stage and helps identify individuals at risk for cognitive decline early in the AD continuum.Systematic Review Research on subjective cognitive decline (SCD) and its association with Alzheimer’s disease (AD), as well as investigations into stage-2 of the AD continuum, is quickly expanding, but fluid biomarker evidence is scarce. We conducted a comprehensive review across PubMed, recent meeting abstracts, and oral presentations, focusing on cross-sectional and longitudinal case-control studies, cohort studies, and meta-analyses.Interpretation Our plasma phospho-181 tau (p181) findings provide molecular fluid biomarker evidence for A+SCD as a pre-dementia AD stage (stage-2) distinct from A+CU (stage-1). Plasma p181 assessment aids in identifying individuals at risk of future disease progression early in the AD continuum.Future directions The here proposed concept of SCD as an indicator of stage 2 of the Alzheimer’s disease continuum - supported and stratified by easily accessible blood-based biomarkers - warrants further validation in memory clinics. It could facilitate earlier- and thus even higher-effect - treatments in the pre-dementia stages of AD.HighlightsA+SCD exhibits a distinct trajectory of plasma p181 compared to A+CUHigher plasma p181 levels in A+SCD predict PACC5 decline and transition to MCIPlasma p181 serves as a biomarker that delineates the A+SCD stage from A+CUHighlightsPlasma p181 levels stratify SCD patients, facilitating early interventionsCompeting Interest StatementDavid Berron is a scientific co-founder of neotiv GmbH and owns company shares. Frank Jessen reports grant support from Roche and speaker and advisor honorarium from Abbvie, AC immune, Biogen, Eisai, Grifols, Janssen, Lilly, Novo Nordisk, Roche. Matthis Synofzik has received consultancy honoraria from Ionis, UCB, Prevail, Orphazyme, Servier, Reata, GenOrph, AviadoBio, Biohaven, Solaxa, Biogen, Zevra, and Lilly, all unrelated to the present manuscript. All other authors report no disclosures.Funding StatementThe DELCODE study is funded by the German Center for Neurodegenerative Diseases (Deutsches Zentrum fuer Neurodegenerative Erkrankungen, DZNE), reference number BN012. This work was additionally supported by the Clinician Scientist program "PRECISE.net" funded by the Else Kroener-Fresenius-Stiftung (to DM, and MS), by the EU Joint Programme - Neurodegenerative Disease Research GENFI-PROX grant (2019-02248; to MS). DM is supported by the Clinician Scientist program of the Medical Faculty Tuebingen (459-0-0) and the Elite Program for Postdoctoral researchers of the Baden-Wuerttemberg-Foundation (1.16101.21).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Committee at the Medical Faculty of the Eberhard Karls University and at the University Hospital of Tuebingen (665/2021BO2) gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors